2024
Practical Guide for Implementing Cryogenic Electron Microscopy Structure Determination in Dermatology Research
Lomakin I, Devarkar S, Freniere C, Bunick C. Practical Guide for Implementing Cryogenic Electron Microscopy Structure Determination in Dermatology Research. Journal Of Investigative Dermatology 2024, 145: 22-31. PMID: 39601740, DOI: 10.1016/j.jid.2024.10.594.Peer-Reviewed Original ResearchChemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors
Wang J, Ho M, Bunick C. Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. Journal Of Investigative Dermatology 2024 PMID: 39608668, DOI: 10.1016/j.jid.2024.10.597.Peer-Reviewed Original ResearchTreatment of psoriasisTopical treatmentAtopic dermatitisTopical treatment of atopic dermatitisIncreased cellular cAMP concentrationOral treatment of psoriasisPDE4 inhibitorsTopical treatment of psoriasisTreatment of atopic dermatitisCellular cAMP concentrationAnti-inflammatory effectsPhosphodiesterase-IV inhibitorImmune cellsOral treatmentPDE4 inhibitionSeborrheic dermatitisInflammatory responseCAMP concentrationAdenosine monophosphateRoflumilastDuration of cAMP signalingPDE4CAMP signalingDermatitisApremilastUtilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States
Bunick C, Vleugels R, Lebwohl M, Grada A, Yue E, Wegrzyn L, D'Andrea E. Utilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States. SKIN The Journal Of Cutaneous Medicine 2024, 8: s448. DOI: 10.25251/skin.8.supp.448.Peer-Reviewed Original ResearchSystemic corticosteroid treatmentSystemic corticosteroidsAtopic dermatitisLong-term usersAdvanced therapiesContinuous health insurance enrollmentUsage of non-steroidal anti-inflammatory drugsRelevant proportion of patientsManagement of atopic dermatitisOral systemic corticosteroidsSystemic corticosteroid exposureClinical guidelinesHistory of malignancyProportion of patientsImmuno-mediated diseasesNon-steroidal anti-inflammatory drugsPercentage of patientsAtopic dermatitis patientsIntroduction of advanced therapiesAdvanced systemic treatmentsPopulation-based studyAnti-inflammatory drugsShort-term usersPrescription of biologicsCorticosteroid exposureLong-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
Issa N, Chovatiya R, Talia J, Torres T, Eyerich K, Calimlim B, Yang Y, Pechonkina A, Moreira A, Grada A, Bunick C. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal Of Cutaneous Medicine 2024, 8: s449. DOI: 10.25251/skin.8.supp.449.Peer-Reviewed Original ResearchAtopic dermatitisModerate-to-severe atopic dermatitisLong-term disease controlClinically meaningful responseProlonged systemic therapyProportion of patientsUpadacitinib treatmentOptimal treatment targetsSystemic therapyOptimal treatmentMeaningful responseJAK inhibitorsInterim analysisPatientsUpadacitinibLong-term maintenanceTreatment targetItchingOptimal outcomesWeeksDermatitisDisease controlOutcomesSkinPhase 3Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry
Silverberg J, Gooderham M, Bunick C, Calimlim B, Grada A, Muñoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s450. DOI: 10.25251/skin.8.supp.450.Peer-Reviewed Original ResearchDermatology Life Quality IndexPP-NRSGlobal Assessment ScaleFollow-up visitAtopic dermatitisQuality of lifeReal-world outcomesSkin clearanceLongitudinal analysisRating ScalePeak Pruritus Numerical Rating ScaleInvestigator Global Assessment scaleSix-month follow-up visitPruritus Numerical Rating ScaleClear/almost clear skinEffect of upadacitinibNon-interventional registryDermatology Life Quality Index scoresNumerical rating scaleAssessment ScaleRegistry of adultsTreating atopic dermatitisEveryday clinical practiceLife Quality IndexImpact of ADSwitching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study
Bunick C, Magnolo N, Moore A, Xinghua G, Lynde C, Ibrahim N, Grada A, Levy G, Calimlim B, Wu X, Armendariz Y, Eyerich K. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. SKIN The Journal Of Cutaneous Medicine 2024, 8: s451. DOI: 10.25251/skin.8.supp.451.Peer-Reviewed Original ResearchAtopic dermatitisSafety resultsInadequate responseEczema Area and Severity IndexWeeks post-switchEczematous skin lesionsOral Janus kinaseEffective treatment strategiesClinically meaningful improvementsClinically meaningful outcomesJanus kinaseChronic skin diseaseOptimal treatment targetsClinical responseMonotherapy studiesSkin clearanceSafety profileDupilumabTreatment strategiesInterleukin-13Interleukin-4UpadacitinibSafety signalsSwitch groupInterleukin-13 signalingWhy Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry
Silverberg J, Bunick C, Calimlim B, Grada A, Knapp K, Munoz B, Crawford J, Obi C, Paller A. Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s461. DOI: 10.25251/skin.8.supp.461.Peer-Reviewed Original ResearchPatient-reported outcomesTreat-to-target recommendationsSkin clearanceAtopic dermatitisOptimal treatmentSkin severityNRS-sleepSkin lesionsNRS painOptimal patient outcomesPartial improvementPatient outcomesNear-complete resolutionAtopic dermatitis treatmentReal-world studyMinimal itchingVIGA-ADOptimal treatment targetsEczema/atopic dermatitisDLQI 0/1Logistic regression modelsCross-sectional analysisItch severityOdds ratioDermatitis treatmentEfficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up). British Journal Of Dermatology 2024, ljae404. PMID: 39438067, DOI: 10.1093/bjd/ljae404.Peer-Reviewed Original ResearchAtopic dermatitisSecondary endpointsDose escalationOpen-labelClinical responseSafety profile of upadacitinibSafety signalsResponse to systemic therapyPruritus Numerical Rating ScaleSafety of upadacitinibEczematous skin lesionsWeeks of treatmentNumerical rating scaleSeverity Index reductionsChronic skin diseasePost hoc analysisPhase 3b/4Systemic therapyItch responseSystemic treatmentPrimary endpointEczema AreaDupilumabSafety profileSuperior efficacyStructural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis.
Daniele S, Galimberti F, Bunick C. Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis. Journal Of Drugs In Dermatology 2024, 23: 903-904. PMID: 39361690.Peer-Reviewed Original ResearchClindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.
Lain E, Bhatia N, Kircik L, Gold L, Harper J, Bunick C, Guenin E, Baldwin H, Feldman S, Rosso J. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis. Journal Of Drugs In Dermatology 2024, 23: 873-881. PMID: 39361705, DOI: 10.36849/jdd.2024.8484.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsModerate-to-severe acneWeeks of once-daily treatmentInflammatory/noninflammatory lesion countsMild to moderate severityTriple-combination treatmentOnce-daily treatmentBaseline to weekPhase 3 studyTreatment success rateQuality-of-life improvementAcne-specific quality of lifePost hoc analysisCutaneous safety/tolerabilityFixed-doseVehicle gelDouble-blindNoninflammatory lesionsFemale acneNo significant differenceImpact of sexEfficacy measuresLesion countsAdverse eventsTreatment successEvaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products
Kucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Girardi M, Dabestani A, Light D. Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products. Journal Of Investigative Dermatology 2024 PMID: 39384016, DOI: 10.1016/j.jid.2024.09.009.Peer-Reviewed Original Research51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin
Bunick C, Huynh T, Jackson M, Lee L, Kempers S, Mendelsohn A, Eursken B, Ahson A, Raiz J, MC. Teng J. 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin. Journal Of The American Academy Of Dermatology 2024, 91: ab332. DOI: 10.1016/j.jaad.2024.07.1321.Peer-Reviewed Original Research49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trials
van Straalen K, Bunick C, Lobach I, Uhlmann L, Passera A, Alarcon I, Wozniak M, Ravichandran S, Martinez A, da Costa A, Bechara F. 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trials. Journal Of The American Academy Of Dermatology 2024, 91: ab235. DOI: 10.1016/j.jaad.2024.07.932.Peer-Reviewed Original ResearchAlterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2
MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2. Journal Of The American Academy Of Dermatology 2024 PMID: 39173885, DOI: 10.1016/j.jaad.2024.07.1499.Peer-Reviewed Original ResearchThe Human Skin Microbiome in Health: CME Part 1
MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. The Human Skin Microbiome in Health: CME Part 1. Journal Of The American Academy Of Dermatology 2024 PMID: 39168311, DOI: 10.1016/j.jaad.2024.07.1498.Peer-Reviewed Original ResearchHuman skin microbiomeSkin microbiomeMicrobiome-host interactionsMicrobiome-based therapiesMyriad of microorganismsMicrobial ecologyCommensal microbesMicrobiomeMicrobiome alterationsOverall homeostasisAssociated with skin diseasesMicroorganismsIn vitroIntrinsic factorsCME seriesFungiMicrobesAnimal studiesSkin healthBacteriaSkin diseasesEcologyHomeostasisSkinHuman skinMechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin
Lomakin I, Devarkar S, Grada A, Bunick C. Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024, 144: 2553-2561.e3. PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.Peer-Reviewed Original ResearchNetwork of water-mediated interactionsCutibacterium acnesPeptide bond formationNascent peptideWater-mediated interactionsTranslational inhibitionAntibiotic resistanceCryogenic electron microscopyA-resolutionMechanistic basesAntibiotic-based therapiesRRNAAminoacyl groupRibosomeAcne pathogenesisAcne therapyAntibiotic stewardshipClindamycinIncreased resistanceAcne vulgarisClinical targetsAcneAntibioticsPeptideTRNA683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study
Bunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.Peer-Reviewed Original ResearchRisk of MACEModerate-to-severe diseaseIncidence of MACEMACE riskAdverse cardiovascular eventsAtopic dermatitisMatched controlsRheumatoid arthritisCardiovascular diseaseCardiovascular eventsModerate-to-severe atopic dermatitisAssociated with increased MACE riskRelative risk of MACEMultivariate Cox proportional hazards modelRelative riskCohort entry dateModerate-to-severe ADHistory of cardiovascular diseaseAssociated with multiple comorbiditiesIncreased MACE riskHistory of smokingChronic systemic inflammationFollow-up periodCox proportional hazards modelsUS administrative claims data734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.Peer-Reviewed Original ResearchSafety of upadacitinibVenous thromboembolic eventsProportion of patientsAdverse eventsAtopic dermatitisDose escalationSystemic therapyOpen-labelSecondary endpointsAdjudicated major adverse cardiac eventsModerate-to-severe atopic dermatitisResponse to systemic therapyTreatment-emergent adverse eventsWeek 4Major adverse cardiac eventsPruritus Numerical Rating ScaleChronic inflammatory skin diseaseDiscontinuation of study treatmentEczematous skin lesionsOral Janus kinaseSevere adverse eventsAdverse cardiac eventsWeeks of treatmentNumerical rating scaleInflammatory skin disease681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of malignancyModerate-to-severe diseaseCohort entry dateAtopic dermatitisRheumatoid arthritisFollow-upModerate-to-severe atopic dermatitisSkin cancerNon-AD cohortIncidence of malignancyNonmelanoma skin cancerSubgroup of patientsNon-AD controlsFollow-up periodCox proportional hazards modelsChronic liver diseaseEffect of disease activityInternational Classification of Diseases (ICD)-9Population-based studyProportional hazards modelClinformatics Data MartSystemic therapyClaims-based studyOptum Clinformatics Data Mart696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Prajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.Peer-Reviewed Original ResearchSkin symptom severityPatient-reported outcomesAtopic dermatitisSkin painClinically meaningful improvementsUpadacitinib monotherapyPatients treated with upadacitinibPatients randomized to placeboSkin symptomsMeaningful improvementsQuality of lifeTreating moderate-to-severe ADModerate-to-severe ADPhase 3 studyDoses of upadacitinibMinimal clinically important differenceSustained improvementJanus kinase inhibitorsClinically important differenceEvaluate long-term benefitsReduced quality of lifeEczema AreaDLQI 0/1Symptom severityKinase inhibitors